Business Wire

euNetworks Expands Its Long Haul Network to Warsaw and Bratislava, Delivering Three Routes Into Poland to Meet Bandwidth Demand

14.12.2021 14:25:00 EET | Business Wire | Press release

Share

euNetworks Group Limited (“euNetworks”), a Western European bandwidth infrastructure company, today announced that it has expanded its long haul network into Poland, delivering three new routes to Warsaw. These routes deliver around 2,977km of newly lit fibre connecting Warsaw directly with Berlin and Hamburg, with the third route via Brno, supporting traffic to Prague, Bratislava and Vienna. This expansion, which took 9 months to deliver, supports euNetworks’ customers’ demand for better diversity into the region. The system is in service, carrying multiple Terabits of customer traffic on each span that will rapidly grow.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005710/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

euNetworks' 3 long routes to Warsaw (Graphic: Business Wire)

The new long haul routes were designed to deliver a unique triverse topology to market. Each route lands in a separate data centre in Warsaw, with scope to further expand as new data centres come into service in the region. The north route is 924km long, extends from Berlin and Hamburg and is unique in the market. Its route diversity also enables customers to bypass Berlin should they need to. The middle route is 845km long, running from euNetworks’ Berlin data centre facility into Warsaw. The south route, at 1,178km, delivers the shortest path to market between Vienna and Warsaw and enables Bratislava in Slovakia as a new point of presence for euNetworks along the way.

These routes connect into the key data centres and data centre hubs in Warsaw. This investment supports euNetworks’ customers’ bandwidth needs in this important market as well as onwards diversity and triversity to the rest of Europe. euNetworks’ long haul network now spans 17 countries, connecting 53 cities. Combined with euNetworks’ extensive metro networks in 17 cities, the long haul network enables any data centre to any data centre connectivity between all these metros on their owned and operated fibre, end-to-end.

The expansion East follows deployment of additional critical infrastructure linking the UK and the Netherlands, with euNetworks’ latest Super Highway along with subsea cable Scylla going live in September 2021.

“Warsaw is an exciting new region for data centre growth and is an important market experiencing strong bandwidth growth,” said Paula Cogan, President, euNetworks. “It’s a growing cloud region in Europe, with its geographic position making it a key connectivity hub for hyperscalers and cloud service providers. We continue to develop our network in support of our customers’ bandwidth requirements across Europe. Our expansion into Poland enables us to continue to offer a seamless and end to end data centre connectivity experience for our customers on our network with the same service delivery and support experience they have come to value.”

euNetworks’ 100g and 400G Wavelengths, 1G and 10G Ethernet, Cloud Connect and Multi Service Port products and solutions are now available in Warsaw, with plans for additional direct connection to further data centres in the region and in Warsaw to support customers’ needs in the future.

euNetworks builds and invests in its city and long haul fibre networks to connect the key data centres and data centre hubs across Europe. The company builds Super Highways on long haul routes that are critical to Europe’s future international bandwidth needs and uses low loss fibre on these routes to deliver a low cost per bit long haul solution for its customers.

About euNetworks

euNetworks is a bandwidth infrastructure company, owning and operating 17 fibre based metropolitan networks connected with a high capacity intercity backbone covering 53 cities in 17 countries across Europe. The company leads the market in data centre connectivity, directly connecting over 465 today. euNetworks is also a leading cloud connectivity provider and offers a targeted portfolio of metropolitan and long haul services including Dark Fibre, Wavelengths, and Ethernet. Wholesale, finance, content, media, mobile, data centre and enterprise customers benefit from euNetworks’ unique inventory of fibre and duct based assets that are tailored to fulfil their high bandwidth needs. For further information visit eunetworks.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

euNetworks contact:
Hannah Britt |
Senior Director, Marketing & IR | euNetworks
hannah.britt@eunetworks.com email
| +44 7717 896 446 mobile

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 11:00:00 EET | Press release

OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with

New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 11:00:00 EET | Press release

ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro

IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 11:00:00 EET | Press release

The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying the foundations for the evolution of AI-supported oncological diagnostics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210610418/en/ On this

Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 11:00:00 EET | Press release

Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 10:15:00 EET | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living with NT1. NT1 is a chronic, rare neurological disease caused by a loss of orexin and characterized by excessive daytime sleepiness and cataplexy (sudden loss of muscle tone). This results in a spectrum of physical, cognitive and psychosocial effects that can have a debilitating impact on many aspects of a person’s life, including work, education and social interactio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye